AI Article Synopsis
- Canine urothelial carcinoma (UC) and prostatic carcinoma (PC) are challenging to diagnose due to their locations, but the BRAF V595E mutation can aid in detection.
- A new conventional PCR method was developed to identify this mutation in urine and prostatic wash samples from dogs, as existing digital PCR methods require equipment that's not widely available.
- The study found a 51.6% mutation detection rate in tissue samples and 53.2% in liquid samples, suggesting that this PCR method is a reliable non-invasive screening tool for these cancers in dogs.
Article Abstract
Canine urothelial carcinoma (UC) and prostatic carcinoma (PC) often present diagnostic challenges due to their anatomical locations. The BRAF V595E mutation, analogous to the human BRAF V600E mutation, has been identified in UC and PC. Digital PCR of urine is a non-invasive diagnostic method of mutation detection, but the availability of the necessary equipment is limited. This study aimed to develop a conventional PCR to detect the BRAF V595E mutation in urine and prostatic wash specimens from dogs with UC or PC. Specific primers for detecting wild-type and mutant BRAF V595E genes were validated in 34 formalin-fixed paraffin-embedded (FFPE) tissues, 116 urine samples, and 9 prostatic wash specimens. The results showed that the BRAF V595E mutation detection rate for UC and PC in the tissues was 51.6%. The detection rate in liquid specimens from dogs with lower urinary tract or prostate masses was 53.2%. Of the 41 cases with follow-up, 16 were further diagnosed with UC or PC, with 75% of liquid specimens from these dogs showing the BRAF V595E mutation. This conventional PCR method provides a reliable and non-invasive screening tool for UC and PC in dogs, especially in settings without advanced equipment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11394148 | PMC |
| http://dx.doi.org/10.3390/ani14172535 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of Mutated Kinase in Canine Carcinomas-An Immunohistochemical Study.
Vet Sci
November 2024
Institute of Animal Pathology, COMPATH, University of Bern, 3012 Bern, Switzerland.
Alterations of the gene and the resulting changes in the BRAF protein are one example of molecular cancer profiling in humans and dogs. We tested 227 samples of canine carcinomas from different anatomical sites (anal sac ( = 23), intestine ( = 21), liver ( = 21), lungs ( = 19), mammary gland ( = 20), nasal cavity ( = 21), oral epithelium ( = 18), ovary ( = 20), prostate ( = 21), thyroid gland ( = 21), urinary bladder ( = 22)) with two commercially available primary anti-BRAF antibodies (VE1 Ventana, VE1 Abcam). The immunohistochemical results were confirmed with droplet digital PCR (ddPCR).
View Article and Find Full Text PDFDiagnostic Value of Conventional Polymerase Chain Reaction for Detecting BRAF V595E Mutation in Liquid and Tissue Specimens of Canine Urothelial and Prostate Carcinomas.
Animals (Basel)
August 2024
Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd., Taipei City 106, Taiwan.
Article Synopsis
- Canine urothelial carcinoma (UC) and prostatic carcinoma (PC) are challenging to diagnose due to their locations, but the BRAF V595E mutation can aid in detection.
- A new conventional PCR method was developed to identify this mutation in urine and prostatic wash samples from dogs, as existing digital PCR methods require equipment that's not widely available.
- The study found a 51.6% mutation detection rate in tissue samples and 53.2% in liquid samples, suggesting that this PCR method is a reliable non-invasive screening tool for these cancers in dogs.
Hotspot Exon 15 Mutations in BRAF Are Uncommon in Feline Tumours.
Vet Comp Oncol
September 2024
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA.
BRAF is one of multiple RAF proteins responsible for the activation of the MAPK cell signalling cascade involved in cell growth, differentiation, and survival. A hotspot BRAF mutation, in exon 15, was determined to be a driver in 100% hairy cell leukaemias, 50%-60% of human melanomas, 30%-50% of human thyroid carcinomas and 10%-20% of human colorectal carcinomas. The orthologous BRAF mutation was seen in 67% and 80% of canine bladder transitional cell carcinomas and prostatic adenocarcinomas, respectively.
View Article and Find Full Text PDFEffective detection of BRAF mutation in canine urothelial and prostate carcinomas using immunohistochemistry.
Vet Comp Oncol
June 2024
Institute of Animal Pathology, University of Bern, Bern, Switzerland.
Canine urothelial carcinoma (UC) and prostate carcinoma (PC) frequently exhibit the BRAF mutation, akin to the BRAF mutation common in various human cancers. Since the initial discovery of the BRAF mutation in canine cancers in 2015, PCR has been the standard method for its detection in both liquid and tissue biopsies. Considering the similarity between the canine BRAF and human BRAF mutations, we hypothesized that immunohistochemistry (IHC) using a BRAF-specific antibody could effectively identify the canine mutant BRAF protein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!